Mar. Drugs 2014, 12(1), 317-351; doi:10.3390/md12010317

Thiopeptide Antibiotics: Retrospective and Recent Advances

1,2email, 1,2,3,4email and 1,2,5,* email
Received: 27 November 2013; in revised form: 13 December 2013 / Accepted: 16 December 2013 / Published: 17 January 2014
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Thiopeptides, or thiazolyl peptides, are a relatively new family of antibiotics that already counts with more than one hundred different entities. Although they are mainly isolated from soil bacteria, during the last decade, new members have been isolated from marine samples. Far from being limited to their innate antibacterial activity, thiopeptides have been found to possess a wide range of biological properties, including anticancer, antiplasmodial, immunosuppressive, etc. In spite of their ribosomal origin, these highly posttranslationally processed peptides have posed a fascinating synthetic challenge, prompting the development of various methodologies and strategies. Regardless of their limited solubility, intensive investigations are bringing thiopeptide derivatives closer to the clinic, where they are likely to show their veritable therapeutic potential.
Keywords: thiopeptides; antibiotics; natural products; peptides; heterocycles; thiazole; oxazole; dehydroamino acids; pyridine
PDF Full-text Download PDF Full-Text [2638 KB, uploaded 17 January 2014 14:15 CET]

Export to BibTeX |

MDPI and ACS Style

Just-Baringo, X.; Albericio, F.; Álvarez, M. Thiopeptide Antibiotics: Retrospective and Recent Advances. Mar. Drugs 2014, 12, 317-351.

AMA Style

Just-Baringo X, Albericio F, Álvarez M. Thiopeptide Antibiotics: Retrospective and Recent Advances. Marine Drugs. 2014; 12(1):317-351.

Chicago/Turabian Style

Just-Baringo, Xavier; Albericio, Fernando; Álvarez, Mercedes. 2014. "Thiopeptide Antibiotics: Retrospective and Recent Advances." Mar. Drugs 12, no. 1: 317-351.

Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert